Overview

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
Phase:
PHASE3
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Gemcitabine
Injections
Paclitaxel
Topotecan